GW's Gover on Cannabis-Derived Drug for Rare Epilepsy (Audio)

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Justin Gover, CEO of GW Pharmaceuticals, on the drug pipeline for the UK- based company which has been developing drug treatments derived from cannabis for decades.